STAT+: Pharmalittle: We’re Reading About a Review of Alzheimer’s Drugs, FDA Interest in Compounded Peptides, and More

Why It Matters

The pricing revelations intensify pressure on lawmakers to revisit drug‑price agreements, and the Alzheimer’s review could reshape investment and regulatory focus on disease‑modifying treatments.

Key Takeaways

• Senate report finds Trump‑linked drug deals raised prices sharply
• Companies earned $177 billion profit during Trump’s second term
• New Alzheimer’s drug review deems clinical benefit negligible
• Experts criticize review for lumping dissimilar monoclonal antibodies together
• Leqembi and Kisunla still show cognitive‑decline slowing

Pulse Analysis

The Senate Health, Education, Labor and Pensions Committee’s latest report underscores a growing disconnect between political rhetoric and pharmaceutical pricing trends. While President Trump repeatedly pledged that voluntary agreements with drugmakers would rein in costs, the data reveal that firms involved in those deals have not only increased list prices—some gene‑therapy and oncology products now exceed $350,000 annually—but also generated $177 billion in profit during his second term, up from $107 billion previously. This stark contrast fuels bipartisan calls for stricter price‑control mechanisms and greater transparency in pricing negotiations.

In parallel, a comprehensive Cochrane review of a decade’s worth of Alzheimer’s research casts doubt on the therapeutic value of the newest anti‑amyloid monoclonal antibodies. By aggregating outcomes from seven different drugs, the analysis concluded that overall clinical benefit is negligible, prompting backlash from neurologists who argue that the review oversimplifies distinct mechanisms and efficacy profiles. Notably, the two most recent agents, Leqembi and Kisunla, demonstrated measurable slowing of cognitive decline, leading to FDA approval and offering patients limited but real benefit. The controversy highlights the challenges of evaluating heterogeneous biologics within a single meta‑analysis framework.

Together, these developments illustrate the tension between market forces, regulatory oversight, and patient expectations. Rising drug prices threaten affordability, especially for high‑cost therapies, while ambiguous efficacy signals in Alzheimer’s treatment risk diverting research funds from more promising avenues. Stakeholders—from policymakers to investors—must navigate a landscape where cost containment and evidence‑based innovation are increasingly intertwined, shaping the next wave of health‑care strategy in the United States.